OM
APLS

Opaleye Management’s Apellis Pharmaceuticals APLS Stock Holding History

Opaleye Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-115,000
Closed -$2.24M – 45
2019
Q1 		$2.24M Sell
115,000
-160,000
-58% -$2.52M 0.62% 44
2018
Q4 		$3.63M Sell
275,000
-100,000
-27% -$1.53M 1.35% 23
2018
Q3 		$6.67M Buy
375,000
+110,000
+42% +$2.03M 1.7% 21
2018
Q2 		$5.83M Buy
+265,000
New +$6.09M 1.51% 26

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Opaleye Management's APLS Position: Q2 2019 in Review

Opaleye Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2019, closing a stake of 115,000 shares — an estimated $2.24M sold.

Opaleye Management first reported a position in APLS in Q2 2018 and held it in 4 quarters. The position peaked at $6.67M in Q3 2018. 99 funds tracked by Wall St. Rank hold APLS as of Q2 2019.

  • Opaleye Management reported no remaining Apellis Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Opaleye Management sold 115,000 Apellis Pharmaceuticals shares in Q2 2019, an estimated $2.24M.
  • Opaleye Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Opaleye Management's Apellis Pharmaceuticals position peaked at $6.67M in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.